Approximately 7,700 people in England are living with the genetic bleeding disorder and males are disproportionately affected.
The condition results from insufficient levels of functioning factor VIII, a protein that is essential for blood clotting, and patients can experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages.
Altuvoct, which can be given as a once-weekly injection, is designed to replace the missing factor VIII, helping the blood to clot and providing temporary control of the disorder…
